- Home
- AXL vs BCAX Comparison
AXL vs BCAX Comparison
Compare AXL & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXL
- BCAX
- Stock Information
- Founded
- AXL 1994
- BCAX 2018
- Country
- AXL United States
- BCAX United States
- Employees
- AXL N/A
- BCAX N/A
- Industry
- AXL Auto Parts:O.E.M.
- BCAX
- Sector
- AXL Consumer Discretionary
- BCAX
- Exchange
- AXL Nasdaq
- BCAX NYSE
- Market Cap
- AXL 519.7M
- BCAX 487.6M
- IPO Year
- AXL 1999
- BCAX 2024
- Fundamental
- Price
- AXL $4.44
- BCAX $9.71
- Analyst Decision
- AXL Hold
- BCAX Strong Buy
- Analyst Count
- AXL 7
- BCAX 7
- Target Price
- AXL $5.64
- BCAX $29.17
- AVG Volume (30 Days)
- AXL 3.4M
- BCAX 675.0K
- Earning Date
- AXL 08-08-2025
- BCAX 08-16-2025
- Dividend Yield
- AXL N/A
- BCAX N/A
- EPS Growth
- AXL N/A
- BCAX N/A
- EPS
- AXL 0.18
- BCAX N/A
- Revenue
- AXL $5,929,300,000.00
- BCAX N/A
- Revenue This Year
- AXL N/A
- BCAX N/A
- Revenue Next Year
- AXL N/A
- BCAX N/A
- P/E Ratio
- AXL $25.18
- BCAX N/A
- Revenue Growth
- AXL N/A
- BCAX N/A
- 52 Week Low
- AXL $3.00
- BCAX $7.80
- 52 Week High
- AXL $7.65
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- AXL 57.37
- BCAX N/A
- Support Level
- AXL $4.26
- BCAX N/A
- Resistance Level
- AXL $4.49
- BCAX N/A
- Average True Range (ATR)
- AXL 0.15
- BCAX 0.00
- MACD
- AXL 0.03
- BCAX 0.00
- Stochastic Oscillator
- AXL 92.73
- BCAX 0.00
About AXL American Axle & Manufacturing Holdings Inc.
American Axle & Mfg Holdings Inc is engaged in manufacturing, engineering, designing, and validation of driveline systems and related components and chassis modules for light trucks, SUVs, crossover vehicles, passenger cars, and commercial vehicles. The company's segment includes Driveline and Metal Forming. It generates maximum revenue from the Driveline segment.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.